tradingkey.logo

Bausch + Lomb Corp

BLCO
17.000USD
+0.590+3.60%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
6.02BMarktkapitalisierung
VerlustKGV TTM

Bausch + Lomb Corp

17.000
+0.590+3.60%

mehr Informationen über Bausch + Lomb Corp Unternehmen

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Bausch + Lomb Corp Informationen

BörsenkürzelBLCO
Name des UnternehmensBausch + Lomb Corp
IPO-datumMay 06, 2022
CEOSaunders (Brenton L)
Anzahl der mitarbeiter13500
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse520 Applewood Crescent
StadtVAUGHAN
BörseNASDAQ OMX NASDAQ Basic NYSE
LandCanada
PostleitzahlL4K 4B4
Telefon19082552864
Websitehttps://ir.bausch.com/
BörsenkürzelBLCO
IPO-datumMay 06, 2022
CEOSaunders (Brenton L)

Führungskräfte von Bausch + Lomb Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%

Aktionärsstatistik

Aktualisiert: Sat, Nov 22
Aktualisiert: Sat, Nov 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Andere
8.54%
Aktionäre
Aktionäre
Anteil
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Andere
8.54%
Aktionärstypen
Aktionäre
Anteil
Corporation
87.65%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.02%
Research Firm
1.67%
Investment Advisor
1.62%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bausch Health Companies Inc
310.45M
87.65%
--
--
Mar 24, 2025
Icahn Enterprises LP
3.50M
0.99%
--
--
Sep 30, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+89.90K
+2.64%
Sep 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
3.25M
0.92%
+724.19K
+28.72%
Sep 30, 2025
GoldenTree Asset Management, LP
2.66M
0.75%
+77.32K
+2.99%
Sep 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
--
--
Sep 30, 2025
Silver Point Capital, L.P.
2.56M
0.72%
+2.56M
--
Sep 30, 2025
Fidelity Management & Research Company LLC
1.56M
0.44%
+788.29K
+102.13%
Sep 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
--
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
Mehr Anzeigen
Ballast Small/Mid Cap ETF
Anteil1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
Anteil0.03%
BNY Mellon US Small Cap Core Equity ETF
Anteil0.03%
Schwab Fundamental International Small Equity ETF
Anteil0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Anteil0%
Invesco Zacks Mid-Cap ETF
Anteil0%
QRAFT AI-Enhanced US Large Cap ETF
Anteil0%
AltShares Event-Driven ETF
Anteil0%
DFA Dimensional International Core Equity 2 ETF
Anteil0%
BNY Mellon US Mid Cap Core Equity ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI